Effect of Galacto-oligosaccharides (GOS) on Faecal Gut Microbiota in Adult Women
Launched by WAGENINGEN UNIVERSITY AND RESEARCH · Feb 27, 2023
Trial Information
Current as of May 11, 2025
Completed
Keywords
ClinConnect Summary
This randomized, parallel, double-blinded intervention study of 6 weeks will include 88 females, who will consume GOS for three consecutive weeks. Faecal samples will be collected at several time points to measure microbiota composition.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Apparently healthy women
- • Aged between 40 - 70 year
- • Body Mass Index (BMI) between 18.5 - 30 kg/m2
- Exclusion Criteria:
- • Having a gastro-intestinal disease, such as celiac disease, Crohn's disease, Ulcerative colitis, or diagnosed irritable bowel syndrome;
- • Having a history of intestinal surgery that might interfere with study outcomes. This does not include an appendectomy or cholecystectomy;
- • Diagnosed with diabetes mellitus;
- • Use of medication that may influence the study results, such as laxatives, lactase preparations, metformin, antibiotics, proton pomp inhibitors, antipsychotics, NSAID's (judged by our research physician);
- • Self-perceived and diagnosed constipation;
- • Having a food allergy to cow's milk or being lactose intolerant;
- • Self-reported slimming, medically prescribed or other diets
- • Reported weight loss or weight gain of \>5kg in the month prior to screening
- • Use of (foods with) pre-, pro-, syn- and/or postbiotics\* (should be stopped at least 4 weeks before the start of the study), or other supplements that can influence the study results (to be determined by the medical investigator);
- • History of side effects with the use of prebiotic supplements
- • Use of antibiotic treatment less than 3 months before start of the study
- • Pregnant or lactating (or having the wish to become pregnant during the study period, self-reported);
- • Not able to comply with study procedures;
- • Use of drugs (should be stopped at least 4 weeks before the study);
- • Alcohol intake ≥7 glasses of alcoholic beverages per week, on average
- • Participation in another clinical trial at the same time;
- • Being an employee of the Food, Health \& Consumer Research group of Wageningen Food \& Biobased Research or employee of FrieslandCampina R\&D.
About Wageningen University And Research
Wageningen University & Research (WUR) is a leading institution in the fields of life sciences, agricultural research, and environmental sustainability. With a strong commitment to advancing knowledge and fostering innovation, WUR conducts interdisciplinary research that addresses global challenges related to food security, climate change, and public health. The university collaborates with various stakeholders, including industry, government, and non-profit organizations, to translate research findings into practical solutions. Through its rigorous clinical trials and research initiatives, WUR aims to improve health outcomes and promote sustainable practices, positioning itself as a pivotal player in enhancing the well-being of both people and the planet.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wageningen, Gelderland, Netherlands
Patients applied
Trial Officials
Maartje van den Belt, Msc
Principal Investigator
Wageningen Food and Biobased Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials